KarXT: A New Era in Antipsychotics?

In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia?
Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D.
• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 80
• How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained